<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font15 { font-size : 15; } .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font19 { font-size : 19; } .font20 { font-size : 20; } .font21 { font-size : 21; } .font22 { font-size : 22; } .font23 { font-size : 23; } .font24 { font-size : 24; } .font26 { font-size : 26; } .font27 { font-size : 27; } .font28 { font-size : 28; } .font30 { font-size : 30; }</style>
 <body>
  <p>
   <span class="font30">trial </span>
   <span class="font28">HIV </span>
   <span class="font27">children </span>
   <span class="font26">pregnant </span>
   <span class="font26">versus </span>
   <span class="font24">women </span>
   <span class="font23">Health </span>
   <span class="font23">clinical </span>
   <span class="font23">treatment </span>
   <span class="font22">trials </span>
   <span class="font21">HIV-infected </span>
   <span class="font20">South </span>
   <span class="font20">years </span>
   <span class="font20">;():–. </span>
   <span class="font20">safety </span>
   <span class="font19">MDR </span>
   <span class="font19">drug </span>
   <span class="font19">drugs </span>
   <span class="font19">studies </span>
   <span class="font18">III </span>
   <span class="font18">Open-label, </span>
   <span class="font18">data </span>
   <span class="font17">[]. </span>
   <span class="font17">pregnancy </span>
   <span class="font17">NIH </span>
   <span class="font17">weeks </span>
   <span class="font17">randomized </span>
   <span class="font17">disease </span>
   <span class="font17">study </span>
   <span class="font16">months </span>
   <span class="font16">populations </span>
   <span class="font16">Drug </span>
   <span class="font16">Trials </span>
   <span class="font16">children, </span>
   <span class="font16">Clinical </span>
   <span class="font16">Development </span>
   <span class="font16">old), </span>
   <span class="font16">Africa </span>
   <span class="font15">LTBI </span>
   <span class="font15">regimen </span>
   <span class="font15">Institute </span>
   <span class="font15">NICHD </span>
   <span class="font15">Phase </span>
   <span class="font15">Yes </span>
   <span class="font15">key </span>
   <span class="font15">lactating </span>
   <span class="font15">persons </span>
   <span class="font15">potential </span>
   <span class="font15">National </span>
   <span class="font14">Dis. </span>
   <span class="font14">Tuberculosis </span>
   <span class="font14">regimens </span>
   <span class="font14">risk </span>
   <span class="font14">{border-style </span>
   <span class="font14">Enrolling </span>
   <span class="font14">development </span>
   <span class="font14">tuberculosis </span>
   <span class="font14">//. </span>
   <span class="font14">AIDS </span>
   <span class="font14">BDQ </span>
   <span class="font14">Epub </span>
   <span class="font14">Human </span>
   <span class="font14">IMPAACT </span>
   <span class="font14">PK, </span>
   <span class="font14">adults </span>
   <span class="font14">efficacy </span>
   <span class="font14">inclusion </span>
   <span class="font14">px;} </span>
   <span class="font14">#ffffff;} </span>
   <span class="font14">Adults </span>
   <span class="font14">Infect </span>
   <span class="font14">International </span>
   <span class="font14">Medicine </span>
   <span class="font14">Pregnant </span>
   <span class="font14">adult </span>
   <span class="font14">doses </span>
   <span class="font14">including </span>
   <span class="font14">postpartum </span>
   <span class="font14">safety, </span>
   <span class="font13">NIAID, </span>
   <span class="font13">design </span>
   <span class="font13">therapy </span>
   <span class="font13">&amp;lt; </span>
   <span class="font13">Available </span>
   <span class="font13">Child </span>
   <span class="font13">Sciences </span>
   <span class="font13">TB, </span>
   <span class="font13">World </span>
   <span class="font13">from: </span>
   <span class="font13">new </span>
   <span class="font13">outcomes </span>
   <span class="font13">women, </span>
   <span class="font13">ART </span>
   <span class="font13">Children </span>
   <span class="font13">[cited </span>
   <span class="font13">adolescents </span>
   <span class="font13">age </span>
   <span class="font13">based </span>
   <span class="font13">isoniazid </span>
   <span class="font13">pediatric </span>
   <span class="font13">Africa, </span>
   <span class="font13">Clin </span>
   <span class="font13">Efficacy </span>
   <span class="font13">Med. </span>
   <span class="font13">Research </span>
   <span class="font13">[,]. </span>
   <span class="font13">first-line </span>
   <span class="font13">include </span>
   <span class="font13">infants </span>
   <span class="font13">use </span>
   <span class="font12">ARVs </span>
   <span class="font12">Fully </span>
   <span class="font12">OBR </span>
   <span class="font12">Pathogens </span>
   <span class="font12">benefits </span>
   <span class="font12">dosing </span>
   <span class="font12">exclusion </span>
   <span class="font12">http://dx.doi.org/./National </span>
   <span class="font12">particularly </span>
   <span class="font12">pulmonary </span>
   <span class="font12">ACTG </span>
   <span class="font12">I/II </span>
   <span class="font12">NCT </span>
   <span class="font12">accrued </span>
   <span class="font12">considerations </span>
   <span class="font12">therapeutic </span>
   <span class="font12">&amp;gt; </span>
   <span class="font12">(Table </span>
   <span class="font12">CD, </span>
   <span class="font12">Children, </span>
   <span class="font12">Engl </span>
   <span class="font12">Food </span>
   <span class="font12">HIV/−, </span>
   <span class="font12">Inclusion </span>
   <span class="font12">India, </span>
   <span class="font12">Infectious </span>
   <span class="font12">Study </span>
   <span class="font12">Women </span>
   <span class="font12">adverse </span>
   <span class="font12">child </span>
   <span class="font12">collab: </span>
   <span class="font12">evidence </span>
   <span class="font12">exposure </span>
   <span class="font12">household </span>
   <span class="font12">require </span>
   <span class="font12">second-line </span>
   <span class="font12">tolerability </span>
   <span class="font12">used </span>
   <span class="font12">(any </span>
   <span class="font12">(i.e., </span>
   <span class="font12">-month </span>
   <span class="font12">Department </span>
   <span class="font12">Disease </span>
   <span class="font12">Maternal </span>
   <span class="font12">Pregnancy </span>
   <span class="font12">Treatment </span>
   <span class="font12">access </span>
   <span class="font12">antiretroviral </span>
   <span class="font12">cases </span>
   <span class="font12">children. </span>
   <span class="font12">currently </span>
   <span class="font12">daily </span>
   <span class="font12">drug–drug </span>
   <span class="font12">especially </span>
   <span class="font12">expected </span>
   <span class="font12">important </span>
   <span class="font12">included </span>
   <span class="font12">modeling </span>
   <span class="font12">prevention </span>
   <span class="font12">preventive </span>
   <span class="font12">research </span>
   <span class="font12">response </span>
   <span class="font12">risks </span>
   <span class="font12">trials, </span>
   <span class="font11">Control </span>
   <span class="font11">DDIs </span>
   <span class="font11">FDA </span>
   <span class="font11">Global </span>
   <span class="font11">However, </span>
   <span class="font11">Infants </span>
   <span class="font11">Institutes </span>
   <span class="font11">Multicenter, </span>
   <span class="font11">Pediatric </span>
   <span class="font11">Possible </span>
   <span class="font11">United </span>
   <span class="font11">active </span>
   <span class="font11">criteria </span>
   <span class="font11">documented </span>
   <span class="font11">higher </span>
   <span class="font11">human </span>
   <span class="font11">infants, </span>
   <span class="font11">inform </span>
   <span class="font11">latent </span>
   <span class="font11">optimal </span>
   <span class="font11">outcome </span>
   <span class="font11">population </span>
   <span class="font11">px; </span>
   <span class="font11">randomized, </span>
   <span class="font11">recommendations </span>
   <span class="font11">shortened </span>
   <span class="font11">tolerability, </span>
   <span class="font11">trials. </span>
   <span class="font11">using </span>
   <span class="font11">young </span>
   <span class="font11">{font-family </span>
   <span class="font11">Adolescent </span>
   <span class="font11">Agency </span>
   <span class="font11">Allergy </span>
   <span class="font11">A–C </span>
   <span class="font11">Centers </span>
   <span class="font11">DS/DR </span>
   <span class="font11">HIV, </span>
   <span class="font11">HIV/− </span>
   <span class="font11">HIV–TB-coinfected </span>
   <span class="font11">Le, </span>
   <span class="font11">Medical </span>
   <span class="font11">NIAID </span>
   <span class="font11">Population </span>
   <span class="font11">Retroviruses </span>
   <span class="font11">States </span>
   <span class="font11">TBD </span>
   <span class="font11">TBTC </span>
   <span class="font11">UMAIhttp://orcid.org/---GuptaAmita </span>
   <span class="font11">adults. </span>
   <span class="font11">and/or </span>
   <span class="font11">appropriate </span>
   <span class="font11">assess </span>
   <span class="font11">cells/mm </span>
   <span class="font11">compatible </span>
   <span class="font11">contacts </span>
   <span class="font11">controlled </span>
   <span class="font11">dose </span>
   <span class="font11">early </span>
   <span class="font11">font-size </span>
   <span class="font11">mortality </span>
   <span class="font11">needed </span>
   <span class="font11">regulatory </span>
   <span class="font11">reproductive </span>
   <span class="font11">results </span>
   <span class="font11">review </span>
   <span class="font11">rifapentine </span>
   <span class="font11">specific </span>
   <span class="font11">start </span>
   <span class="font11">therapies </span>
   <span class="font11">weekly </span>
   <span class="font11">years), </span>
   <span class="font11">ATT </span>
   <span class="font11">Biology </span>
   <span class="font11">CDC </span>
   <span class="font11">DDI </span>
   <span class="font11">Design </span>
   <span class="font11">IPT </span>
   <span class="font11">Mo, </span>
   <span class="font11">Ongoing </span>
   <span class="font11">Organization; </span>
   <span class="font11">Planned </span>
   <span class="font11">Safety </span>
   <span class="font11">Safety, </span>
   <span class="font11">TB-related </span>
   <span class="font11">Trial </span>
   <span class="font11">Viral </span>
   <span class="font11">adequate </span>
   <span class="font11">advanced </span>
   <span class="font11">approved </span>
   <span class="font11">background </span>
   <span class="font11">careful </span>
   <span class="font11">category </span>
   <span class="font11">conducted </span>
   <span class="font11">contraceptives </span>
   <span class="font11">diagnosis </span>
   <span class="font11">differ </span>
   <span class="font11">dose-finding </span>
   <span class="font11">double; </span>
   <span class="font11">effects </span>
   <span class="font11">enrollment </span>
   <span class="font11">forms </span>
   <span class="font11">formulations </span>
   <span class="font11">global </span>
   <span class="font11">high-quality </span>
   <span class="font11">infant </span>
   <span class="font11">infection </span>
   <span class="font11">interactions </span>
   <span class="font11">likely </span>
   <span class="font11">major </span>
   <span class="font11">nonrandomized </span>
   <span class="font11">open-label, </span>
   <span class="font11">placebo </span>
   <span class="font11">populations. </span>
   <span class="font11">postmarketing </span>
   <span class="font11">rifapentine; </span>
   <span class="font11">small </span>
   <span class="font11">spectrum </span>
   <span class="font11">stated </span>
   <span class="font11">status </span>
   <span class="font11">supported </span>
   <span class="font11">toxicity </span>
   <span class="font11">tuberculosis. </span>
   <span class="font11">way </span>
   <span class="font11">women. </span>
   <span class="font11">(minimal </span>
   <span class="font11">./NEJMoa </span>
   <span class="font11">ART, </span>
   <span class="font11">Administration; </span>
   <span class="font11">Alliance </span>
   <span class="font11">Dec </span>
   <span class="font11">Diseases </span>
   <span class="font11">Efficacy, </span>
   <span class="font11">HIV. </span>
   <span class="font11">HP, </span>
   <span class="font11">IIb </span>
   <span class="font11">Immunodeficiency </span>
   <span class="font11">Isoniazid </span>
   <span class="font11">LPV/r </span>
   <span class="font11">LTBI, </span>
   <span class="font11">Lancet </span>
   <span class="font11">Life </span>
   <span class="font11">Lung </span>
   <span class="font11">NVP </span>
   <span class="font11">Network </span>
   <span class="font11">Organization. </span>
   <span class="font11">PK/PD </span>
   <span class="font11">Thailand, </span>
   <span class="font11">Uganda, </span>
   <span class="font11">WHO, </span>
   <span class="font11">adolescents, </span>
   <span class="font11">adults, </span>
   <span class="font11">analysis </span>
   <span class="font11">antituberculosis </span>
   <span class="font11">border-color </span>
   <span class="font11">border-width </span>
   <span class="font11">case </span>
   <span class="font11">consideration </span>
   <span class="font11">considered </span>
   <span class="font11">consultation </span>
   <span class="font11">critical </span>
   <span class="font11">developing </span>
   <span class="font11">diagnostic </span>
   <span class="font11">different </span>
   <span class="font11">effect </span>
   <span class="font11">example, </span>
   <span class="font11">excluded </span>
   <span class="font11">fetal </span>
   <span class="font11">followed </span>
   <span class="font11">guidance </span>
   <span class="font11">high-dose </span>
   <span class="font11">hormonal </span>
   <span class="font11">impact </span>
   <span class="font11">increased </span>
   <span class="font11">interactions, </span>
   <span class="font11">international </span>
   <span class="font11">known </span>
   <span class="font11">low </span>
   <span class="font11">lower </span>
   <span class="font11">month </span>
   <span class="font11">noninferiority </span>
   <span class="font11">old) </span>
   <span class="font11">old, </span>
   <span class="font11">optimized </span>
   <span class="font11">oral </span>
   <span class="font11">paucibacillary </span>
   <span class="font11">people </span>
   <span class="font11">resistant </span>
   <span class="font11">reverse </span>
   <span class="font11">shorter </span>
   <span class="font11">similar </span>
   <span class="font11">sites </span>
   <span class="font11">solid; </span>
   <span class="font11">standard </span>
   <span class="font11">status, </span>
   <span class="font11">technical </span>
   <span class="font11">therapeutics </span>
   <span class="font11">therapy; </span>
   <span class="font11">transcriptase </span>
   <span class="font11">week </span>
   <span class="font11">{font-style </span>
   <span class="font11">{font-weight </span>
   <span class="font10">(&amp;lt; </span>
   <span class="font10">./S-()- </span>
   <span class="font10">./journal.pmed..tTable </span>
   <span class="font10">ARV)/HIV− </span>
   <span class="font10">Abbreviations: </span>
   <span class="font10">Adolescents </span>
   <span class="font10">Adults, </span>
   <span class="font10">CDC, </span>
   <span class="font10">Daily </span>
   <span class="font10">De, </span>
   <span class="font10">Development; </span>
   <span class="font10">Eunice </span>
   <span class="font10">European </span>
   <span class="font10">GA) </span>
   <span class="font10">Group </span>
   <span class="font10">GuptaA, </span>
   <span class="font10">HIV/HIV−, </span>
   <span class="font10">HIV− </span>
   <span class="font10">Int </span>
   <span class="font10">Kennedy </span>
   <span class="font10">Lentivirus: </span>
   <span class="font10">Li, </span>
   <span class="font10">MDR, </span>
   <span class="font10">MRC </span>
   <span class="font10">MSF, </span>
   <span class="font10">Microbial </span>
   <span class="font10">Microbiology </span>
   <span class="font10">NRTIs </span>
   <span class="font10">Network; </span>
   <span class="font10">Opportunistic </span>
   <span class="font10">Organisms </span>
   <span class="font10">Organization </span>
   <span class="font10">Overview </span>
   <span class="font10">Peru, </span>
   <span class="font10">Shriver </span>
   <span class="font10">Special </span>
   <span class="font10">Viruses </span>
   <span class="font10">Viruses: </span>
   <span class="font10">Zimbabwe </span>
   <span class="font10">[Internet]. </span>
   <span class="font10">antibiotic </span>
   <span class="font10">approach </span>
   <span class="font10">approximately </span>
   <span class="font10">benefit </span>
   <span class="font10">better </span>
   <span class="font10">bold </span>
   <span class="font10">breast </span>
   <span class="font10">burden </span>
   <span class="font10">care </span>
   <span class="font10">challenges </span>
   <span class="font10">compared </span>
   <span class="font10">compelling </span>
   <span class="font10">concerns </span>
   <span class="font10">courier; </span>
   <span class="font10">culture </span>
   <span class="font10">de-escalation </span>
   <span class="font10">deaths </span>
   <span class="font10">designs </span>
   <span class="font10">despite </span>
   <span class="font10">disease, </span>
   <span class="font10">disseminated </span>
   <span class="font10">drug-resistant </span>
   <span class="font10">drug-resistant; </span>
   <span class="font10">drugs; </span>
   <span class="font10">duration </span>
   <span class="font10">em; </span>
   <span class="font10">ensure </span>
   <span class="font10">estimated </span>
   <span class="font10">evaluate </span>
   <span class="font10">example </span>
   <span class="font10">extremely </span>
   <span class="font10">fetal, </span>
   <span class="font10">formulation </span>
   <span class="font10">gestational </span>
   <span class="font10">greater </span>
   <span class="font10">guidelines </span>
   <span class="font10">high </span>
   <span class="font10">immunodeficiency </span>
   <span class="font10">information </span>
   <span class="font10">inhibitor; </span>
   <span class="font10">initiation </span>
   <span class="font10">investigational </span>
   <span class="font10">isoniazid; </span>
   <span class="font10">lactation </span>
   <span class="font10">limited </span>
   <span class="font10">maternal </span>
   <span class="font10">mg/kg </span>
   <span class="font10">multidrug-resistant </span>
   <span class="font10">nested </span>
   <span class="font10">nonpregnant </span>
   <span class="font10">occurred </span>
   <span class="font10">old </span>
   <span class="font10">outcomes. </span>
   <span class="font10">participants </span>
   <span class="font10">patients </span>
   <span class="font10">pharmacokinetics; </span>
   <span class="font10">planned </span>
   <span class="font10">positive </span>
   <span class="font10">postpartum/lactating </span>
   <span class="font10">pregnancy, </span>
   <span class="font10">progression </span>
   <span class="font10">pt;} </span>
   <span class="font10">randomization </span>
   <span class="font10">recent </span>
   <span class="font10">remain </span>
   <span class="font10">reviewed </span>
   <span class="font10">routinely </span>
   <span class="font10">severe </span>
   <span class="font10">studied </span>
   <span class="font10">studies, </span>
   <span class="font10">targeted </span>
   <span class="font10">test </span>
   <span class="font10">timing </span>
   <span class="font10">treating </span>
   <span class="font10">type </span>
   <span class="font10">uninfected </span>
  </p>
 </body>
</html>
